Erasca, Inc. (ERAS)
NASDAQ$1.465
Market Cap
$415.61M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
248 of 924
Rank in Industry
141 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ERAS Insider Trading Activity
ERAS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $181,920 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Casdin Alexander W. | director | 1 | $181,920 | 0 | $0 | $181,920 |
About Erasca, Inc.
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients …
Insider Activity of Erasca, Inc.
Over the last 12 months, insiders at Erasca, Inc. have bought $181,920 and sold $0 worth of Erasca, Inc. stock.
On average, over the past 5 years, insiders at Erasca, Inc. have bought $6.78M and sold $3.75M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Casdin Alexander W. (director) — $181,920.
The last purchase of 80,000 shares for transaction amount of $181,920 was made by Casdin Alexander W. (director) on 2024‑05‑21.
List of Insider Buy and Sell Transactions, Erasca, Inc.
| 2024-05-21 | Casdin Alexander W. | director | 80,000 0.0447% | $2.27 | $181,920 | +10.64% | ||
| 2023-12-06 | Lim Jonathan E | Chairman & CEO | 278,150 0.1825% | $1.72 | $478,418 | +35.84% | ||
| 2023-12-06 | Start Valerie Denise Harding | director | 10,000 0.007% | $1.85 | $18,480 | +35.84% | ||
| 2023-12-05 | Lim Jonathan E | Chairman & CEO | 721,850 0.4606% | $1.69 | $1.22M | +34.29% | ||
| 2023-12-04 | Casdin Alexander W. | director | 30,000 0.0197% | $1.66 | $49,785 | +39.88% | ||
| 2023-10-05 | Lim Jonathan E | Chairman & CEO | 1M 0.695% | $2.03 | $2.03M | +4.25% | ||
| 2023-06-08 | Lim Jonathan E | Chairman & CEO | 100,000 0.0676% | $2.75 | $275,000 | -18.38% | ||
| 2023-04-10 | Casdin Alexander W. | director | 20,000 0.0135% | $2.76 | $55,230 | -14.44% | ||
| 2023-03-28 | Lim Jonathan E | Chairman & CEO | 100,000 0.0693% | $2.84 | $284,000 | -12.41% | ||
| 2023-01-10 | Lim Jonathan E | Chairman & CEO | 60,000 0.0413% | $3.86 | $231,420 | -29.33% | ||
| 2022-12-21 | Bristol James Arthur | director | 20,000 0.0162% | $4.14 | $82,800 | -35.48% | ||
| 2022-12-21 | Start Valerie Denise Harding | director | 10,000 0.0091% | $4.64 | $46,400 | -35.48% | ||
| 2022-12-15 | Casdin Alexander W. | director | 20,000 0.0167% | $4.87 | $97,490 | -42.77% | ||
| 2022-12-14 | Lim Jonathan E | Chairman & CEO | 40,000 0.0338% | $4.99 | $199,600 | -43.49% | ||
| 2022-12-13 | Chen Bihua | director | 307,692 0.3325% | $6.50 | $2M | -44.42% | ||
| 2021-08-10 | Chen Bihua | director | 200,000 0.2202% | $22.10 | $4.42M | -41.38% | ||
| 2021-07-26 | Sale | Chen Bihua | director | 200,000 0.2009% | $18.77 | $3.75M | -35.23% | |
| 2021-07-20 | Chen Bihua | director | 950,000 0.7974% | $16.00 | $15.2M | -35.39% | ||
| 2021-07-20 | Multani Pratik S | director | 6,200 0.0052% | $16.00 | $99,200 | -35.39% | ||
| 2021-07-20 | Hambleton Julie | director | 6,000 0.005% | $16.00 | $96,000 | -35.39% |
Total: 22
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Casdin Alexander W. | director | 573974 0.203% | $843,741.78 | 4 | 0 | <0.0001% |
| Lim Jonathan E | Chairman & CEO | 12899360 4.5625% | $18.96M | 7 | 0 | <0.0001% |
| Chen Bihua | director | 10813246 3.8246% | $15.9M | 3 | 1 | <0.0001% |
| Multani Pratik S | director | 172866 0.0611% | $254,113.02 | 1 | 0 | <0.0001% |
| Start Valerie Denise Harding | director | 20000 0.0071% | $29,400.00 | 3 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$14,527,743 | 76 | 38.40% | $473.67M | |
$84,871,118 | 57 | 17.71% | $406.62M | |
$24,384,691 | 42 | -30.27% | $400.47M | |
Erasca, Inc. (ERAS) | $26,923,982 | 20 | -17.22% | $415.61M |
$6,280,187 | 19 | 6.80% | $482.63M |
ERAS Institutional Investors: Active Positions
| Increased Positions | 78 | +57.35% | 15M | +6.27% |
| Decreased Positions | 54 | -39.71% | 17M | -7.47% |
| New Positions | 26 | New | 7M | New |
| Sold Out Positions | 15 | Sold Out | 2M | Sold Out |
| Total Postitions | 160 | +17.65% | 231M | -1.19% |
ERAS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Frazier Life Sciences Management, L.P. | $26,567.00 | 6.85% | 19.39M | 0 | 0% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $22,893.00 | 5.91% | 16.71M | -120,509 | -0.72% | 2024-12-31 |
| Vr Adviser, Llc | $22,216.00 | 5.73% | 16.22M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $21,593.00 | 5.57% | 15.76M | +404,684 | +2.63% | 2024-12-31 |
| Vanguard Group Inc | $17,363.00 | 4.48% | 12.67M | -614,840 | -4.63% | 2024-12-31 |
| Logos Global Management Lp | $17,125.00 | 4.42% | 12.5M | +2M | +14.68% | 2024-12-31 |
| Suvretta Capital Management, Llc | $16,872.00 | 4.35% | 12.32M | -1M | -10.55% | 2024-12-31 |
| Arch Venture Management, Llc | $15,146.00 | 3.91% | 11.06M | 0 | 0% | 2024-12-31 |
| Paradigm Biocapital Advisors Lp | $14,731.00 | 3.8% | 10.75M | +84,213 | +0.79% | 2024-12-31 |
| Siren, L.L.C. | $12,134.00 | 3.13% | 8.86M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.